IP Library › Granted Patent US 9,700,596
Granted Patent B2
US 9,700,596 · App. 14/003,060 · Granted Jul 11, 2017

Locally released growth factors to mediate motor recovery after stroke

Inventors: Stanley T. Carmichael (Sherman Oaks, CA); Andrew N. Clarkson (Dunedin, NZ)
Assignee: The Regents of the University of California
A61K38/185A61K9/0085A61K9/06A61K31/40A61K31/445A61K31/727A61K31/728A61K31/737A61K38/18A61K47/36A61K47/42A61L27/3834A61L27/52A61L27/54A61L2300/414A61L2300/602A61L2300/64A61L2430/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,700,596
App. No.
14/003,060
Granted
Jul 11, 2017
Kind
B2
Abstract

Methods of improving recovery of a mammal after an ischemic event (e.g., stroke) are provided. In various embodiments the methods involve administering a neural growth factor (e.g., BDNF) into the infarct (e.g., stroke) cavity in a biocompatible hydrogel formulation. In certain embodiments the hydrogel comprises a thiolated hyaluronan and a thiolated gelatin with an optional thiolated heparin.

Claims (11)

1. A method of improving recovery of a mammal after cerebral ischemia, said method comprising:

administering a therapeutically effective amount of a hydrogel containing BDNF into the infarct cavity in the brain of said mammal, wherein said administering comprises depositing said hydrogel into said infarct cavity, wherein said hydrogel provides sustained release of said BDNF over time, and wherein said hydrogel is not administered until at least 7 days after the onset of the ischemic event.

2. The method of claim 1 , wherein said hydrogel comprises a biopolymer.

3. The method of claim 2 , wherein said hydrogel comprises one or more materials selected from the group consisting of hyaluronan, gelatin, thiol-modified hyaluronan, heparin, thiol-modified heparin, thiol-modified chondroitin sulfate, thiol-modified gelatin, a hyaluronan sodium salt, and an acrylated hyaluronic acid.

4. The method of claim 1 , wherein said hydrogel comprises a hyaluronan derivative and a gelatin derivative.

5. The method of claim 4 , wherein hyaluronan derivative comprises a thiolated hyaluronan.

6. The method of claim 4 , wherein said gelatin derivative comprises a thiolated gelatin.

7. The method of claim 5 , wherein said thiolated hyaluronan and thiolated gelatin have each been thiol-modified using carbodiimide mediated hydrazide chemistry.

8. The method of claim 4 , wherein said hydrogel further comprises heparin or a heparin derivative.

9. The method of claim 8 , wherein said hydrogel comprises a thiol-modified heparin.

10. The method of claim 1 , wherein said administering comprises injecting said hydrogel into said ischemic cavity.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2013
From: CARMICHAEL, STANLEY T.; CLARKSON, ANDREW N.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 031183/0274 →
Continuity (2)
Provisional Application 61449435 · Mar 4, 2011
Related Publication 20140315805A1 · Oct 23, 2014